Literature DB >> 17161681

Practices and pitfalls of mouse cancer models in drug discovery.

Andrew L Kung1.   

Abstract

Mouse models of cancer are critical tools for elucidating mechanisms of cancer development, as well as for assessment of putative cancer therapies. However, there are ongoing concerns about the value of mouse cancer models for predicting therapeutic efficacy in humans. This chapter reviews the most commonly used transplanted tumor models, including subcutaneous and orthotopic tumors in mice. It also reviews commonly utilized in vivo study endpoints. Even small improvements in predictive value achieved through careful selection of models and endpoints have the potential to have large impacts on productivity and overall drug development costs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17161681     DOI: 10.1016/S0065-230X(06)96007-2

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  22 in total

Review 1.  Examining the utility of patient-derived xenograft mouse models.

Authors:  Samuel Aparicio; Manuel Hidalgo; Andrew L Kung
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

2.  Gene Electrotransfer of Canine Interleukin 12 into Canine Melanoma Cell Lines.

Authors:  Ursa Lampreht; Urska Kamensek; Monika Stimac; Gregor Sersa; Natasa Tozon; Masa Bosnjak; Andreja Brozic; Geraldo Gileno de Sá Oliveira; Takayuki Nakagawa; Kohei Saeki; Maja Cemazar
Journal:  J Membr Biol       Date:  2015-04-04       Impact factor: 1.843

Review 3.  Challenges and opportunities in childhood cancer drug development.

Authors:  Robin E Norris; Peter C Adamson
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

4.  Enabling hyperpolarized (129) Xe MR spectroscopy and imaging of pulmonary gas transfer to the red blood cells in transgenic mice expressing human hemoglobin.

Authors:  Matthew S Freeman; Zackary I Cleveland; Yi Qi; Bastiaan Driehuys
Journal:  Magn Reson Med       Date:  2013-09-04       Impact factor: 4.668

5.  Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Authors:  Sandra Pérez-Torras; Anna Vidal-Pla; Rosa Miquel; Vanessa Almendro; Laureano Fernández-Cruz; Salvador Navarro; Joan Maurel; Neus Carbó; Pere Gascón; Adela Mazo
Journal:  Cell Oncol (Dordr)       Date:  2011-06-17       Impact factor: 6.730

6.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

7.  A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

Authors:  Eric Guerin; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

8.  Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

Authors:  David S Ziegler; Renee D Wright; Santosh Kesari; Madeleine E Lemieux; Mary A Tran; Monish Jain; Leigh Zawel; Andrew L Kung
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

9.  Models for prevention and treatment of cancer: problems vs promises.

Authors:  Bharat B Aggarwal; Divya Danda; Shan Gupta; Prashasnika Gehlot
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

Review 10.  Nanoparticle characterization: state of the art, challenges, and emerging technologies.

Authors:  Eun Jung Cho; Hillary Holback; Karen C Liu; Sara A Abouelmagd; Joonyoung Park; Yoon Yeo
Journal:  Mol Pharm       Date:  2013-03-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.